A study of a new pill for tumors with KRAS G12D mutation
Part of Cancer clinical trials.
This trial tests a new oral pill called HS-10529 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth, and to check its safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your cancer must be advanced and you must have tried standard treatments that either stopped working or caused too many side effects.
- You need to have at least one tumor that can be measured on imaging scans.
- You must agree to provide a tumor tissue sample (either from a past biopsy or a new one).
- You should be generally active and able to take care of yourself (ECOG performance status 0 or 1).
- You cannot have had previous treatment with a KRAS G12D inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HS-10370 given along with other anticancer treatments for advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if this combination is safe and effective for people who have run out of standard options.
This trial tests a new oral medication (GFH375) for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if the drug can shrink tumors or slow cancer growth.
This trial tests a new drug called HS-10370 combined with other anti-cancer treatments for people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if this combination can shrink or control tumors better than other options.
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
This trial tests a new drug called HS-10541, which may target a specific genetic change in your tumor (KRAS G12C mutation). The study aims to see if this drug is safe and effective, either alone or with other cancer treatments, for people with advanced cancer that hasn't responded to standard therapy.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.